SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
PLAINSBORO, N.J., Nov. 21, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conference in November:
- At 10:00M ET on Tuesday, November 29, 2016, Mr. Robert Davis, President Specialty Surgical Solutions, will present at the 28th Annual Piper Jaffray Healthcare Conference in New York City, N.Y. This presentation will be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
